2Seventy CEO Leschly to step down as company cuts staff, spending

Nearly two years after splitting off from Bluebird bio, cancer drug developer 2Seventy bio is cutting 40% of its workforce and reducing spending in a restructuring meant to fund its operations into at least 2026.

Nick Leschly, the longtime Bluebird CEO who became 2Seventy’s head when the companies split, will also step down once a successor is identified, 2Seventy said in a statement Tuesday.